- Component A: Full-year 2026 revenue of $447.190 million, representing an 18.7% increase from the prior year (+$70.626 million)
- *Twist Bioscience's fiscal year begins on October 1
The current model EXCLUDES the following assets and assumptions:
- Licensing deals for antibody drug candidates discovered with Twist's technology platform
- DNA data storage initiatives (deprioritized by the business)
.svg)
.svg)
.svg)
.svg)
-cropped.svg){kind=small}
.svg)
.svg)
